Monday, March 24, 2008 8:33:59 AM
“Juno only showed a benifit (sic) when another UNAPROVED (sic) drug was used” I have been following this company from the beginning – this is news to me. Just what are you talking about.?
“The database was seriously flawed” You are correct. I was a statistician in the early years of my scientific career. Frequently trials do not go as planned and require revised statistical procedures and often more data gathering. IDMI had to do the latter. The trial for Junovan (M-MTP-PE) had issues that only could be resolved by a follow up (more data gathering) of the patients who received the treatment. The initial FDA rejection was based on incomplete data. The follow up of the trial patients provided enough data to show that there is a statistical benefit for the use of Junovan. The recent positive news indicates to me that we should have smooth sailing with Junovan to FDA approval.
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM